CERo Therapeutics (CERO) Competitors $0.08 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends CERO vs. OCX, AFMD, ANEB, UNCY, AADI, TARA, LVTX, MNPR, ATRA, and IMMXShould you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include OncoCyte (OCX), Affimed (AFMD), Anebulo Pharmaceuticals (ANEB), Unicycive Therapeutics (UNCY), Aadi Bioscience (AADI), Protara Therapeutics (TARA), LAVA Therapeutics (LVTX), Monopar Therapeutics (MNPR), Atara Biotherapeutics (ATRA), and Immix Biopharma (IMMX). These companies are all part of the "pharmaceutical products" industry. CERo Therapeutics vs. OncoCyte Affimed Anebulo Pharmaceuticals Unicycive Therapeutics Aadi Bioscience Protara Therapeutics LAVA Therapeutics Monopar Therapeutics Atara Biotherapeutics Immix Biopharma OncoCyte (NASDAQ:OCX) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings, community ranking and media sentiment. Which has more risk & volatility, OCX or CERO? OncoCyte has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, CERo Therapeutics has a beta of -0.5, suggesting that its share price is 150% less volatile than the S&P 500. Does the media favor OCX or CERO? In the previous week, OncoCyte had 2 more articles in the media than CERo Therapeutics. MarketBeat recorded 2 mentions for OncoCyte and 0 mentions for CERo Therapeutics. CERo Therapeutics' average media sentiment score of 0.50 beat OncoCyte's score of 0.30 indicating that CERo Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment OncoCyte Neutral CERo Therapeutics Positive Do analysts rate OCX or CERO? OncoCyte currently has a consensus target price of $4.06, indicating a potential upside of 35.42%. Given OncoCyte's higher possible upside, analysts clearly believe OncoCyte is more favorable than CERo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OncoCyte 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50CERo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has stronger valuation and earnings, OCX or CERO? CERo Therapeutics has lower revenue, but higher earnings than OncoCyte. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncoCyte$1.50M33.66-$27.78MN/AN/ACERo TherapeuticsN/AN/A-$2.54MN/AN/A Does the MarketBeat Community prefer OCX or CERO? OncoCyte received 8 more outperform votes than CERo Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformOncoCyteOutperform Votes88.42%Underperform Votes8791.58% CERo TherapeuticsN/AN/A Is OCX or CERO more profitable? CERo Therapeutics has a net margin of 0.00% compared to OncoCyte's net margin of -3,558.46%. CERo Therapeutics' return on equity of 0.00% beat OncoCyte's return on equity.Company Net Margins Return on Equity Return on Assets OncoCyte-3,558.46% -149.88% -45.79% CERo Therapeutics N/A N/A -67.60% Do insiders and institutionals hold more shares of OCX or CERO? 55.4% of OncoCyte shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 1.6% of OncoCyte shares are owned by company insiders. Comparatively, 18.0% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryOncoCyte beats CERo Therapeutics on 8 of the 13 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get CERo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERO vs. The Competition Export to ExcelMetricCERo TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.49M$3.14B$5.50B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E RatioN/A12.03116.1015.23Price / SalesN/A400.761,496.2597.74Price / CashN/A149.0039.7434.10Price / Book-0.034.024.775.07Net Income-$2.54M-$42.25M$119.06M$225.46M7 Day PerformanceN/A8.04%0.80%0.37%1 Month PerformanceN/A8.69%5.65%3.57%1 Year PerformanceN/A32.09%36.75%29.43% CERo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CEROCERo TherapeuticsN/A$0.08flatN/AN/A$12.49MN/A0.008Gap DownOCXOncoCyte2.1563 of 5 stars$2.99-1.0%$4.06+35.9%+29.3%$50.34M$1.02M0.00120Analyst ForecastAFMDAffimed3.7626 of 5 stars$3.22-3.6%$20.00+521.1%-8.3%$49.03M$2.68M0.0076News CoveragePositive NewsANEBAnebulo Pharmaceuticals3.2458 of 5 stars$1.88+1.6%$8.00+325.5%-16.3%$48.75MN/A-5.884Gap DownUNCYUnicycive Therapeutics2.9993 of 5 stars$0.52+1.1%$5.13+894.4%-10.7%$48.63M$680,000.00-0.499Gap UpAADIAadi Bioscience4.2055 of 5 stars$1.96flat$10.25+423.0%-53.9%$48.25M$23.82M-0.8140Upcoming EarningsTARAProtara Therapeutics2.157 of 5 stars$2.31-1.3%$24.00+939.0%+105.8%$47.66MN/A-0.7230Positive NewsLVTXLAVA Therapeutics2.3512 of 5 stars$1.85-3.6%$6.00+224.3%+61.0%$46.90M$7.40M-2.0360Positive NewsGap DownMNPRMonopar Therapeutics3.9794 of 5 stars$13.25-9.7%$22.00+66.0%+432.0%$46.64MN/A-5.7610ATRAAtara Biotherapeutics3.5786 of 5 stars$9.25-3.4%$14.00+51.4%-69.2%$44.56M$62.39M-0.24165Upcoming EarningsGap UpIMMXImmix Biopharma3.8268 of 5 stars$1.60-3.0%$7.00+337.5%-52.1%$43.92MN/A-1.909Positive News Related Companies and Tools Related Companies OCX Alternatives AFMD Alternatives ANEB Alternatives UNCY Alternatives AADI Alternatives TARA Alternatives LVTX Alternatives MNPR Alternatives ATRA Alternatives IMMX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CERO) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
